Irish firm Bio-Medical Research announced today the creation of 170 new jobs after its subsidiary Slendertone won approval from the US Food and Drugs Administration for a number of its products.
Until now Slendertone’s products could only be sold on prescription in the US but now can be sold through retail networks.
In a statement the company said the market in the US will be worth $50 million in the first year and that approximately half the new jobs will be in Ireland.
Bio-Medical Research makes medical products for the treatment of muscle disorders and employs 400 people between its headquarters in Galway, its manufacturing plant in Donegal and its other bases in Europe and the US.
READ SOME MORE
The company is to seek a stock exchange listing in 2003.
